Fig. 2From: Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trialsPatients with serum potassium (K+) levels (a) ≤ 5.5 mmol/L and (b) ≤ 5.0 mmol/L at various time pointsBack to article page